Advertisement
ACRS Novinky na Forexe
Aclaris Therapeutics Says Will Discontinue Further Development Of ATI-450 Program
Biopharmaceutical company Aclaris Therapeutics, Inc. (ACRS) announced Monday top-line results from a Phase 2b study of zunsemetinib (ATI-450), an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis.
RTTNews
|
Pred 555 dňami
Aclaris Therapeutics, Pediatrix Therapeutics Ink License Deal For ATI-1777 In Greater China
Biopharmaceutical company Aclaris Therapeutics, Inc. (ACRS) and Chinese therapeutic company Pediatrix Therapeutics, Inc. announced that the companies have entered into a license agreement.
RTTNews
|
Pred 904 dňami
